Brepocitinib Overview & RVT-3101 Update
RVT-3101 Offers Transformative Potential in Biologic-Experienced Patients
who are Biomarker Positive
Clinical Remission (Modified Mayo)
in Biologic-Experienced Patients
■RVT-3101 Placebo ■Comparator Placebo
Endoscopic Improvement
in Biologic-Experienced Patients
■RVT-3101 Placebo ■Comparator Placebo.
45%
Pbo-adj A = 41%
40%
p = 0.03, NS
35%
41%
30%
Pbo-adj A =22%
25%
24%
20%
15%
10%
5%
0%
0%
Biomarker Positive
Expected P3 Dose
Rinvoq
1%
65%
Pbo-adj A =56%
60%
p = 0.005
55%
56%
50%
45%
40%
35%
Pbo-adj A=29%
30%
32%
25%
Pbo-adj A 11%
Pbo-adj A9%
20%
Pbo-adj A = 5%
13%
15%
12%
10%
10%
2%
3%
5%
5%
0%
0%
Stelara
Zeposia
mirikizumab
Biomarker Positive
Expected P3 Dose
Rinvoq
Pbo-adj A 14%
21%
Pbo-adj A 10%
15%
3%
7%
Not
Reported
5%
Stelara
Zeposia
mirikizumab
Figures reflect cross-trial comparison and not results from a head-to-head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.
Data for comparators come from respective Phase 3 studies except for mirikizumab where Phase 2 data are presented (biologic-experienced subset not reported in Phase 3)
•
roivant Clinical Remission reported for RVT-3101 requires stool frequency ≤ 1 and 21 point reduction from baseline, rectal bleeding frequency = 0, and endoscopic score ≤ 1
•
•
Clinical Remission reported for Rinvoq requires stool frequency ≤1 and 20 point reduction from baseline, rectal bleeding frequency = 0, and endoscopic score ≤ 1
Clinical Remission reported for Stelara requires stool frequency ≤ 3, rectal bleeding frequency = 0, and endoscopic score ≤ 1
For RVT-3101, some biologic experienced patients had also received a JAK inhibitor. Rinvoq data exclude patients with prior JAK exposure and reflect weighted average across the two
Phase 3 studies. Mirikizumab data reflect weighted average of 200mg/600mg dose groups in their Phase 2 study.
12
For investor audiences onlyView entire presentation